聚乙二醇干扰素治疗慢性乙型病毒性肝炎疗效预测指标的研究进展被引量：1

Research progress on predictors for efficacy of pegylated interferon in the treatment of chronic hepatitis B

导出

摘要在我国尽管乙型肝炎疫苗早已纳入免疫规划管理,大大降低了乙型肝炎病毒(HBV)感染的发生率,但抗病毒治疗仍是目前唯一减缓或预防疾病进展的方法,其中聚乙二醇干扰素(Peg-IFN)作为一线抗病毒药物,联合免疫调节的双重作用来阻断HBV复制,在有限的疗程中实现更高的HBeAg阴转率、HBsAg清除率以及持续的治疗后效应。但因其价格贵,治疗过程中不良反应多,且仅在三分之一患者中起效而使用受限。

作者唐瑶秦波 TANG Yao;QIN Bo(Department of Infectious Diseases,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区重庆医科大学附属第一医院感染科

出处《中国感染与化疗杂志》北大核心 2025年第2期218-223,共6页 Chinese Journal of Infection and Chemotherapy

基金重庆市科学技术局人才计划(cstc2024ycjh-bgzxm0095)。

关键词慢性乙型病毒性肝炎聚乙二醇干扰素乙型肝炎病毒疗效预测指标

分类号 R512.6 [医药卫生—内科学] R978 [医药卫生—药品]

引文网络
相关文献

参考文献7

1顾琳琳,胡瑞,窦宇明,肖丽.聚乙二醇干扰素α-2b治疗HBeAg阴性慢性乙型肝炎实现临床治愈的预测因素分析[J].肝脏,2023,28(3):313-319. 被引量：6
2王一卓,张崴琪,李红.聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎患者3年随访研究[J].实用肝脏病杂志,2023,26(5):626-629. 被引量：6
3LI Ming Hui,SUN Fang Fang,CHEN Feng Xin,ZENG Zhan,LIN Yan Jie,BI Xiao Yue,YANG Liu,DENG Wen,JIANG Ting Ting,HUANG Rong Hai,YI Wei,XIE Yao.Cytokine Profiles and Virological Marker Monitoring during 48 Weeks Peginterferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B[J].Biomedical and Environmental Sciences,2022,35(4):312-321. 被引量：3
4王倩倩,胡乾坤,张毅,方钟,黄晨璐,许伟,陈良,黄玉仙.抗-HBc半定量水平联合早期病毒学应答预测干扰素治疗慢性乙型肝炎的疗效[J].肝脏,2019,24(9):1002-1006. 被引量：3
5林潇,王晓晓,宋爱心,鲁俊峰,柳雅立,金怡,曹振环,马丽娜,郑燕红,陈新月.乙型肝炎核心抗体定量水平可作为HBsAg清除的预测指标[J].中华肝脏病杂志,2021,29(7):673-678. 被引量：11
6许正锯,王崇国,李旭红,杨红,张启华.干扰素抗体与干扰素α-2a治疗慢性乙型肝炎疗效的关系[J].中华传染病杂志,1998,16(3):178-179. 被引量：13
7Yongjung Park,Jun Yong Park,Kwang-Hyub Han,Hyon-Suk Kim.Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy[J].Hepatobiliary & Pancreatic Diseases International,2012,11(5):499-506. 被引量：3

二级参考文献37

1Peng Hu,Jia Shang,Wenhong Zhang,Guozhong Gong,Yongguo Li,Xinyue Chen,Jianning Jiang,Qing Xie,Xiaoguang Dou,Yongtao Sun,Yufang Li,Yingxia Liu,Guozhen Liu,Dewen Mao,Xiaoling Chi,Hong Tang,Xiaoou Li,Yao Xie,Xiaoping Chen,Jiaji Jiang,Ping Zhao,Jinlin Hou,Zhiliang Gao,Huimin Fan,Jiguang Ding,Dazhi Zhang,Hong Ren.HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog:New Switch Study[J].Journal of Clinical and Translational Hepatology,2018,6(1):25-34. 被引量：102
2Bataller R,Brenner DA.Liver fibrosisThe Journal of Clinical Investigation,2005.
3Lok AS,McMahon BJ.Chronic hepatitis B:update2009. Hepatology . 2009
4Rossmanith W,Schulte-Hermann R.Biology of transforming growth factor beta in hepatocarcinogenesis. Microscopy Research and Technique . 2001
5Yuen M F,Sablon E,Hui C K,et al.Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology . 2001
6Wells RG.The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. Journal of Clinical Gastroenterology . 2005
7MN Ajuebor,CM Hogaboam,T Le,MG Swain.C-C chemokine ligand 2/monocyte chemoattractant protein-1 directly inhibits NKT cell IL-4 production and is hepatoprotective in T cell-mediated hepatitis in the mouse. J Immunol . 2003
8CL Lai,E Gane,YF Liaw,CW Hsu,S Thongsawat,Y Wang.Telbivudine versus lamivudine in patients with chronic hepatitis B. The New England Journal of Medicine . 2007
9Ayada M,Ishikawa T,Okumura A,Tanabe J,Ito H,Ohashi T,Matsumoto E,Sato K,Hotta N,Fukuzawa Y,Kakumu S.Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection. Hepatology Research . 2006
10O kumoto K,Hattori E,Tamura K,Kiso S,Watanabe H,Saito K,et al.Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver International . 2004